Skip to content

Study · Observational study · n = 6,904 · 2026

2 results

Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.

Kishimori T, Kato T, Iwasaki Y, Shimada T, Wada A, Tani A, Yamaji R, Koike J, Matsumoto T, Yagi T, Okada M

Diabetes, obesity & metabolism5 Jan 2026

PMID41492180 (opens in a new tab)DOI10.1111/dom.70433 (opens in a new tab)PepBankPUB-41492180
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In propensity-matched adults with HFpEF and type 2 diabetes, oral semaglutide was associated with a lower 1-year risk of all-cause death than sitagliptin.

    In plain wordsIn adults with heart failure and type 2 diabetes, oral semaglutide was linked to fewer deaths over 1 year than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause death at 1 year
    Study

    n = 6,904

    Comparator
    Sitagliptin
    Analysis
    Primary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    All-cause death
    4.3%
    oral semaglutide
    All-cause death
    7%
    sitagliptin
    hazard ratio
    0.61 ratio
    all-cause death

    Source sentences

    Summary
    Over 1 year, the risk for all-cause death in patients who received oral semaglutide relative to those who received sitagliptin was significantly lower (4.3% [145/3452] vs. 7.0% [229/3452]; log-rank p < 0.001; hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.50 to 0.75).
    1 context sentence
    Summary · context
    After propensity score matching, each group included 3452 patients.
  2. 02HumanObservational studyEfficacy outcome

    In propensity-matched adults with HFpEF and type 2 diabetes, oral semaglutide was associated with fewer hospitalisations than sitagliptin.

    In plain wordsIn adults with heart failure and type 2 diabetes, oral semaglutide was linked to fewer hospital stays than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseHospitalisation at 1 year
    Study

    n = 6,904

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Hospitalisation
    37.1%
    oral semaglutide
    Hospitalisation
    42.4%
    sitagliptin
    hazard ratio
    0.83 ratio
    hospitalisation

    Source sentences

    Summary
    Similarly, patients who received oral semaglutide experienced fewer hospitalisations than those who received sitagliptin (37.1% vs. 42.4%; log-rank p < 0.001; HR, 0.83; 95% CI, 0.77 to 0.90).
    1 context sentence
    Summary · context
    After propensity score matching, each group included 3452 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.